• Recruiting

NCT04244656: Phase 1 -A Safety and Efficacy Study Evaluating CTX120 Relapsed Refractory Myeloma

Updated: Sep 2

NCT04244656: Phase 1 -A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma


CTX120 crispr therapeutics

This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX120 in subjects with relapsed or refractory multiple myeloma.


Sponsor

CRISPR Therapeutics AG


Multiple locations

International study

 

ClinicalTrials.gov Identifier: NCT04244656


A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-BCMA Allogeneic CRISPR-Cas9-Engineered T Cells (CTX120) in Subjects With Relapsed or Refractory Multiple Myeloma


First Posted : January 28, 2020


Click here for details on ClinicalTrials.gov

 

Biological: CTX120

Biological: CTX120

CRISPR/Cas9 gene-edited allogeneic anti-BCMA CAR-T cells CTX120

allogeneic CRISPR-Cas9 engineered anti-BCMA T cells CTX120


CTX120 B-cell maturation antigen (BCMA)-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.


Description: CTX120 is an allogeneic CRISPR/Cas9 gene-edited CAR-T cell therapy targeting BCMA in development for the treatment of multiple myeloma

Gene editing approach: Disruption and insertion

http://www.crisprtx.com/programs/immuno-oncology


 

- Multiple locations

- Illinois: University of Chicago

- Pennsylvania: University of Pennsylvania Philadelphia

- Tennessee: Sarah Cannon Research Institute Nashville

 

Locations

United States, Illinois

United States, Oregon

United States, Pennsylvania

United States, Tennessee

Canada, Ontario

Australia, New South Wales

Australia, Victoria

Spain


Posts Archive